Biospace features Tallac Therapeutics as an antibody-drug conjugate (ADC) drug developer

We’ve been featured in an article titled “Drug Developers Tap the Immune System to Supercharge ADCs” which was published in Biospace this week. This article discusses the growth of the antibody drug conjugate market and explores the potential of immunostimulatory antibody drug conjugates (iADCs).

In this piece, Hong I. Wan, CEO of Tallac Therapeutics, discusses the features of Tallac’s TAC-001, a TLR9 agonist ADC, and how it could potentially benefit a broader patient population with increased safety and tolerability.

Read the full article here: